BRIEF published on 08/21/2024 at 13:05, 29 days 12 hours ago La théralase démontre l'activation de la rutherrine avec un médicament contre le diabète Traitement Du Cancer Theralase Rutherrin Metformine Production De ROS
PRESS RELEASE published on 08/21/2024 at 13:00, 29 days 12 hours ago Theralase(R) Demonstrates Unique Ability to Activate Rutherrin(R) With Diabetes Drug Theralase Technologies Inc. announces innovative cancer treatment using Rutherrin activated by Metformin without light/radiation. Opens new patient care possibilities Innovation Theralase Technologies Inc. Cancer Treatment Rutherrin Metformin
BRIEF published on 08/12/2024 at 13:05, 1 month 7 days ago Theralase publie ses états financiers du deuxième trimestre 2024 Résultats Financiers Placements Privés Traitement Du Cancer Theralase Étude II
BRIEF published on 08/12/2024 at 13:05, 1 month 7 days ago Theralase Releases 2Q2024 Financial Statements Financial Results Private Placements Cancer Treatment Theralase Study II
PRESS RELEASE published on 08/12/2024 at 13:00, 1 month 7 days ago Theralase(R) Release’s 2Q2024 Financial Statements Theralase® Technologies Inc. releases unaudited financial statements for the six-month period ended June 30, 2024. Conference call scheduled to review results. Study II progress and Break Through Designation update discussed Conference Call Financial Statements Theralase Technologies Inc. Break Through Designation Study II
BRIEF published on 07/08/2024 at 23:20, 2 months 11 days ago Theralase Closes $CAN 775,000 in First Tranche of Private Placement Private Placement Cancer Research Theralase Rutherrin Phase II Clinical Study
BRIEF published on 07/08/2024 at 23:20, 2 months 11 days ago Theralase clôture une première tranche de placement privé de 775 000 $CAN Placement Privé Recherche Contre Le Cancer Theralase Rutherrin Étude Clinique De Phase II
PRESS RELEASE published on 07/08/2024 at 23:15, 2 months 11 days ago Theralase(R) Closes $CAN 775,000 in First Tranche of Non-Brokered Private Placement Theralase® closes successful Non-Brokered Private Placement offering to fund cancer research and clinical studies. Proceeds to advance Phase II NMIBC study and Rutherrin® development Non-brokered Private Placement Theralase Technologies Inc. Cancer Research Rutherrin® Phase II NMIBC Study
BRIEF published on 06/20/2024 at 13:05, 2 months 29 days ago Theralase Successfully Repurposes Non-Cancer Drugs for Cancer Therapy Cancer Therapy Theralase Rutherrin Drug Repurposing Preclinical Research
BRIEF published on 06/20/2024 at 13:05, 2 months 29 days ago Theralase réutilise avec succès des médicaments non anticancéreux pour le traitement du cancer Recherche Préclinique Thérapie Contre Le Cancer Theralase Rutherrin Réutilisation De Médicaments
Published on 09/19/2024 at 23:15, 2 hours 41 minutes ago Cypher Metaverse Inc. Announces Second Closing of Financing
Published on 09/19/2024 at 23:00, 2 hours 56 minutes ago WestJet Partners with FLYHT and NOAA to Improve Weather Forecasting in North America
Published on 09/19/2024 at 23:00, 2 hours 56 minutes ago Cerrado Files NI 43-101 Preliminary Economic Assessment Technical Report and Mineral Resource Estimate for The Minera Don Nicolas Mine in Santa Cruz, Argentina
Published on 09/19/2024 at 21:09, 4 hours 46 minutes ago EQS-Adhoc: Mercedes-Benz Group AG adjusts full-year guidance for the year 2024 based on current market outlook
Published on 09/19/2024 at 18:44, 7 hours 11 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 09/19/2024 at 18:03, 7 hours 53 minutes ago Funding Circle Plc: POS-Transaction in Own Shares
Published on 09/19/2024 at 17:52, 8 hours 3 minutes ago PILOT 28 : FIGEAC AÉRO remporte 3 nouveaux contrats sur l'A320 pour 65 millions d'euros
Published on 09/19/2024 at 17:52, 8 hours 3 minutes ago PILOT 28: FIGEAC AÉRO secures 3 new wins on the A320 airframe for 65 million euros
Published on 09/19/2024 at 17:45, 8 hours 11 minutes ago Gimv draagt helft van participatie in Infravest over aan WorxInvest (communicatie in toepassing van artikel 7:97 WVV)
Published on 09/19/2024 at 17:45, 8 hours 11 minutes ago Gimv sells half of participation in Infravest to WorxInvest (communication pursuant to article 7:97 BCAC)
Published on 09/19/2024 at 17:45, 8 hours 11 minutes ago Gimv sells half of participation in Infravest to WorxInvest (communication pursuant to article 7:97 BCAC)